NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy
Chemical Communications · 2023
DOI: 10.1039/d3cc00663h ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Communications, 2023. Verfasst von Guo Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nantong Key Laboratory of Public Health and Medical Analysis, School of Public Health, Nantong University, No. 9, Seyuan Road, Nantong 226019, Jiangs…. Hauptthemen laut MEDLINE: Neoplasms, Prodrugs. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Excellent Youth Foundation of Jiangsu Scientific Committee.
Abstract (Originalsprache)
An NQO1-responsive agonist has been developed to evoke an anti-tumor immune response, providing a new concept for tumor-microenvironment-responsive prodrug design to achieve precise immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nantong Key Laboratory of Public Health and Medical Analysis, School of Public Health, Nantong University, No. 9, Seyuan Road, Nantong 226019, Jiangsu, P. R. China. ylqin@ntu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Excellent Youth Foundation of Jiangsu Scientific Committee
Zitieren
APA
Li, G., Xu, Y., Kong, X., Gu, L., Qin, Y., & Wu, L. (2023). NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy. Chemical Communications. https://doi.org/10.1039/d3cc00663h
Vancouver
Li G, Xu Y, Kong X, Gu L, Qin Y, Wu L. NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy. Chemical Communications. 2023. doi:10.1039/d3cc00663h
BibTeX
@article{Li2023,
author = {Li, Guo and Xu, Yongxiao and Kong, Xiaojie and Gu, Liuwei and Qin, Yuling and Wu, Li},
title = {NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy},
journal = {Chemical Communications},
year = {2023},
doi = {10.1039/d3cc00663h}
}
EUVIMED